Summary of annualized bleed rates during each period of the study
| Period∗,†,‡ . | n . | Overall,§ median (IQR) . | Spontaneous, median (IQR) . | Traumatic, median (IQR) . | Joint, median (IQR) . |
|---|---|---|---|---|---|
| During ITI‖ | 13 | 3.8 (0-10.1) | 0 (0-2.6) | 1 (0-4) | 0 (0-3.1) |
| During tapering¶ | 10 | 0 (0-2.4) | 0 (0-0) | 0 (0-1.3) | 0 (0-0) |
| During follow-up# | 10 | 0 (0-1.5) | 0 (0-0) | 0 (0-0) | 0 (0-0) |
| Period∗,†,‡ . | n . | Overall,§ median (IQR) . | Spontaneous, median (IQR) . | Traumatic, median (IQR) . | Joint, median (IQR) . |
|---|---|---|---|---|---|
| During ITI‖ | 13 | 3.8 (0-10.1) | 0 (0-2.6) | 1 (0-4) | 0 (0-3.1) |
| During tapering¶ | 10 | 0 (0-2.4) | 0 (0-0) | 0 (0-1.3) | 0 (0-0) |
| During follow-up# | 10 | 0 (0-1.5) | 0 (0-0) | 0 (0-0) | 0 (0-0) |
Annualized bleed rate is defined as the number of bleeding episodes divided by length of the noted period in days × 365.25.
Excludes patients observed <90 days within the period.
Only patients who achieved tolerization entered the tapering and follow-up periods.
Overall includes those with 0 ABR.
There were 7 patients (44%) with no bleeds during the ITI period.
There were 6 patients (60%) with no bleeds during the tapering period.
There were 7 patients (70%) with no bleeds during the follow-up period.